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Objectives: The resistance of Streptococcus pneumoniae to the recently available
antibiotic treatment has been a growing problem. The aim of the study was to
determine the quinolone-resistant strains and detect the presence of mutations in
the quinolone resistance-determining regions of the gyrA, parE, and parC genes.
Methods: In this study, for the first time in Iran, the polymerase chain reactione
restriction fragment length polymorphism (PCR-RFLP) method was used to investi-
gate the presence of mutations at quinolone resistance-determining regions of
topoisomerase IV and DNA gyrase on 82 S. pneumoniae strains, among them 45
clinical samples were from patients and 37 from healthy carriers (control group).
Results: In clinical samples, 34 (75.56%) strains contained mutations in the parC
gene, 31 (68.89%) carried mutations in the gyrA gene, and 14 (31.11%) had parE
gene mutations. Antibiotic susceptibility test was performed using the CLSI
(Clinical and Laboratory Standards Institute) criteria on three different genera-
tions of quinolone family, with nalidixic acid (82.22%) showing the highest resis-
tance and levofloxacin (42.22%) the least resistance.
Conclusion: Results indicated that there is a significant correlation between qui-
nolone resistance development and mutations in the parE gene as well as in the
parC and gyrA genes.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
246 M. Kargar, et alyears. Basic identification of the colonies was performed1. Introduction
Streptococcus pneumoniae is an important human
pathogen that causes many diseases such as bacteremia,
acute sinusitis, pneumonia, meningitis, and otitis [1,2].
Development of antibiotic resistance in this species has
become a worldwide problem with serious effects on the
treatment of diseases within the past 20 years [3,4].
Therefore, it is necessary to apply new therapeutic al-
ternatives, such as newer fluoroquinolones that include
levofloxacin and moxifloxacin [5,6]. Fluoroquinolones
such as ciprofloxacin can be a suitable antibiotic to treat
Gram-negative infections [7]. The mechanism of fluo-
roquinolone action involves inhibition of DNA gyrase
and topoisomerase IV. Topoisomerase IV and DNA
gyrase are heterotetramer proteins composed of two
subunits: DNA gyrase, encoded by the genes gyrA and
gyrB, and topoisomerase IV, encoded by the genes parC
and parE. Fluoroquinolone resistance most commonly
develops as a result of a stepwise mutational process in
quinolone resistance-determining regions (QRDRs) of
either the parC/E or the gyrA/B gene [8]. Pneumococcal
resistance to fluoroquinolones is due to mutations in
either gyrA or parC or in both of them. These strains
usually become completely fluoroquinolone resistant
with the addition of a mutation in other target genes
such as parE and gyrB [9]. Several studies have shown
that a significant proportion of isolates harboring mu-
tations in parC or gyrA have low or no phenotypic
expression, but they have the potential to develop higher
levels of resistance to fluoroquinolones when they suf-
fered a mutation in both gyrA and parC resulting in
treatment failure [1,9]. Obviously, rapid detection of a
resistance mechanism in a molecular test would allow
clinicians to initially avoid potentially unsuitable treat-
ment. However, bacteria that give positive results in
genotypic tests may remain phenotypically susceptible.
Therefore, microbiologists concluded that the risk of
resistance developing is adequately probably to warrant
continuation of alternative therapy [10].
The aim of the study was to determine the quinolone-
resistant strains and detect the presence of mutations in
the QRDRs of the gyrA, parE, and parC genes.
2. Materials and methods
2.1. Bacterial and clinical specimens
A total of 82 clinical specimens containing S. pneu-
moniae were collected during 2011e2012 from the pa-
tients admitted to the intensive care units of two hospitals
in Shiraz, Iran. Among them, 45 samples were isolated
from patients with pneumonia, meningitis, and fever, and
37 sampleswere related to healthy controls. Sampleswere
collected from the sputum, blood, and cerebrospinal fluid.
Samples were divided into five groups, with the highest
abundance being observed in the age group of 31e40based on colony characteristics, type of hemolysis, Gram
staining, bile solubility, and the optochin test. Then in
order to confirm the exact isolates, the lytA gene was
amplified by lytA-F (50-CAACCGTACAGAATGAAG
CGG-30) and lytA-R (50-TTA TTC GTG CAA TAC TCG
TGC-30) primers [11]. These primers were provided by
Cinnagen Company (Tehran, Iran). DNA was extracted
using the boiling method. Polymerase chain reaction
(PCR) was performed in 25 mL reaction mixtures con-
taining 1 mL of DNA template, 1 mL of each primer, 1 mL
of MgCl2, 0.5 mL of deoxynucleotide triphosphates, and
0.25 mL of Taq polymerase. The following steps were
followed while performing PCR: initial denaturation at
94C for 5 minutes, followed by 32 cycles consisting of
denaturation at 94C for 1minute, annealing at 58C for 1
minute, extension at 72C for 1 minute, and final exten-
sion at 72C for 8 minutes. Products were analyzed by
electrophoresis on 1% agarose gels and visualized under
UV light after staining with ethidium bromide. After
identification, each strain was subcultured in 20% glyc-
erol in Tryptone soy broth (TSB) (Oxoid, Basingstoke,
UK), and all isolated strains were stored at 70C as
frozen stock.
2.2. Antibiotic susceptibility test
The antibiogram test was performed in order to
measure the susceptibility rate of the strains to quino-
lones, adopting the CLSI standard method. Initially, the
bacteria were cultivated in Nutrient broth (Merck,
Darmstadt, Germany) and incubated at 37C for 2 hours
until the turbidity reached § McFarland standard
(approximately 1.5  10 cells/mL bacteria). Then the
grown bacteria were transferred to MuellereHinton agar
plates (Merck) containing 5% defibrinated sheep blood.
Antibiotic disks, including nalidixic acid (30 mg), cip-
rofloxacin (5 mg), norfloxacin (10 mg), ofloxacin (5 mg),
and levofloxacin (5 mg), were placed on the plates and
then incubated under microaerophilic conditions at 37C
for 16e18 hours. Susceptible, intermediate, and resis-
tant colonies were determined by measuring the diam-
eter of the growth inhibition ring (in millimeters),
according to the manufacturer’s (Rosco, Teardrop,
Denmark) instructions. Escherichia coli Top 10 strain
was used as the standard strain.
2.3. QRDR determination
Polymerase chain reactionerestriction fragment length
polymorphism (PCR-RFLP) was used to amplify frag-
ments of the gyrA, parC, and parE genes. Primers used for
the detection of mutations are shown in Table 1. These
primers were provided by Cinnagen Company (Tehran,
Iran). PCR amplification was carried out in 25 mL reaction
mixture containing 1 mL of DNA template, 1 mL of each
primer, 1 mL of MgCl2, 0.5 mL of deoxynucleotide tri-
phosphates (dNTP), and 0.25 mL of Taq polymerase. After
Table 1. PCR primers for QRDRs of the fluoroquinolone resistance genes.
PCR conditions Amplicon size (bp) Primer (50e30) Gene
One cycle of 5 min at 94C; 32 cycles
of 1 min at 94C, 1 min at 61C,
1 min at 72C; one cycle of 8 min at 72C
360 F: 50-TGG GTT GAA GCC GGT TCA-30
R: 50-TGC TGG CAA GAC CGT TGG-30
parC
One cycle of 5 min at 94C; 32 cycles
of 1 min at 94C, 1 min at 61C,
1 min at 72C; one cycle of 8 min at 72C
290 F: 50-AAG GCG CGT GAT GAG AGC-30
R: 50-TCT GCT CCA ACA CCC GCA-30
parE
One cycle of 5 min at 94C; 32 cycles
of 1 min at 94C, 1 min at 57C, 1 min
at 72C; one cycle of 8 min at 72C
380 F: 50-CCG TCG CAT TCT TTA CG-30
R: 50-AGT TGC TCC ATT AAC CA-30
gyrA
PCR Z polymerase chain reaction; QRDR Z quinolone resistance-determining region.
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digestedwith Sau3A,MspI, andAluI enzymes (Fermentas,
St. Leon-Rot, Germany), respectively. Then RFLP prod-
ucts were separated by electrophoresis on 1.5% (wt/vol.)
agarose gel and visualized under UV light after staining
with ethidium bromide.
2.4. Statistical analysis
The results were analyzed by SPSS software version
15 (SPSS Inc., Chicago, IL, USA), and p < 0.05 was
considered to be statistically significant.3. Results
3.1. Bacteria and antibiotic susceptibility
S. pneumoniae was isolated from 45 patients included
in this study. Of these patients, 16 (35.33%) were male
and 29 (64.45%) were female. In addition, 23 (51.11%)
samples were from patients with pneumonia, 16
(35.55%) were from those with meningitis, and seven
(15.55%) were related to patients having fever. The
resistance percentages of all strains to tested antibiotics
were as follows: nalidixic acid 82.22%, ciprofloxacin
73.33%, ofloxacin 53.33%, norfloxacin 48.89%, and
levofloxacin 42.22% (Table 2). The highest resistance
was observed in patients in the age group of 31e40
years.
3.2. Analysis of PCR-RFLP patterns of QRDR
The results indicated that 34 (75.55%) out of 45
clinical isolates contained mutations in the parC gene,Table 2. Antibiotic susceptibility of S. pneumoniae.
Susceptible (%) Intermediate (%)
4 (8.89) 4 (8.89)
5 (11.11) 7 (15.56)
6 (13.33) 15 (33.33)
8 (7.78) 15 (33.33)
14 (31.11) 12 (26.67)31 (68.89%) had mutations in the gyrA gene, and 14
(31.11%) had mutations in the parE gene. Moreover,
from 37 control samples, nine (24.32%) strains with
mutations in the parC gene, seven (18.99%) with mu-
tations in the gyrA gene, and eight (21.52%) with mu-
tations in the parE gene were observed. Detection of
three DNA fragments of 200 bp, 80 bp, and 80 bp, as a
result of digestion of the 360 bp parC gene amplicons
with Sau3A enzyme, represented the existence of mu-
tations, whereas the observation of two fragments of
200 bp and 160 bp indicated the absence of mutations in
the correspondent gene (Figure 1). Furthermore, the
mutant parE gene gave three fragments of 130 bp,
130 bp, and 30 bp after digestion of the 290 bp ampli-
cons with MspI enzyme, where detection of two frag-
ments of 130 bp and 160 bp suggested the absence of
mutations in this gene (Figure 2). Detection of three
DNA fragments of 180 bp, 140 bp, and 60 bp as a result
of digestion of the 380 bp gyrA gene amplicons with
AluI enzyme represented the existence of mutations,
whereas the observation of two fragments of 200 bp and
180 bp indicated the absence of mutations in the
correspondent gene (Figure 3).
3.3. Statistical analysis
Using statistical analysis, it was illustrated that there
is a significant association between mutations in the
gyrA gene and resistance to all quinolones (nalidixic
acid (p Z 0.048), ciprofloxacin (p Z 0.002), nor-
floxacin (p Z 0), ofloxacin (p Z 0), and levofloxacin
(p Z 0)). Statistical analysis revealed a significant
correlation between mutations in the parC gene and theResistance (%) Antibiotic
37 (82.22) Nalidixic acid
33 (73.33) Ciprofloxacin
24 (53.33) Ofloxacin
22 (48.89) Norfloxacin
19 (42.22) Levofloxacin
Figure 1. PCR-RFLP, parC gene. (A) M, represents 100 bp DNA marker; 1, uncut PCR product (360 bp); and 2, negative
control. (B) M, represents 100 bp DNA marker; 1, products of wild-type strain digestion by Sau3A enzyme giving 200 bp and
160 bp fragments; and 2, products of mutant strain digestion by Sau3A enzyme with 200 bp, 80 bp, and 80 bp fragments.
PCR Z polymerase chain reaction; RFLP Z restriction fragment length polymorphism.
Figure 2. PCR-RFLP, parE gene. (A) M, represents 100 bp DNA marker; 1. negative control; and 2, uncut PCR product (290 bp).
(B) M, represents 100 bp DNA marker; 1, MspI restriction enzyme digestion products of wild-type strain giving 160 bp and 130 bp
fragments; and 2, products of mutant strain digestion by MspI enzyme representing 130 bp, 130 bp, and 30 bp fragments.
PCR Z polymerase chain reaction; RFLP Z restriction fragment length polymorphism.
Figure 3. PCR-RFLP, gyrA gene. (A) M, represents 100 bp DNA marker; 1, products of mutant strains digestion by AluI enzyme
representing 180 bp, 140 bp, and 60 bp fragments; and 2, AluI restriction enzyme digestion products of wild-type strain giving
200 bp and 180 bp fragments. (B) M, represents 100 bp DNA marker; 1, negative control; and 2, uncut PCR product (380 bp).
PCR Z polymerase chain reaction; RFLP Z restriction fragment length polymorphism.
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ciprofloxacin (p Z 0.048), norfloxacin (p Z 0.039),
and levofloxacin (p Z 0.001). However, mutations in
the parE gene indicated a considerable correlation only
with resistance to norfloxacin (p Z 0).T
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.4. Discussion
Considering the seriousness of pneumococcal in-
fections, prevention and treatment of such infections play
a substantial role in social healthcare management. Un-
fortunately, drug abuse led to a worldwide spread of
quinolone-resistant S. pneumoniae strains, especially in
developing countries. Determination of antimicrobial
susceptibility is important, particularly when treatment
has failed. According to studies, the level of resistance to
quinolones in Asian countries, especially in the Middle
East, is significantly higher than that in other parts of the
world; quinolone resistance has been reported in Korea
(6.1%), the Philippines (9.1%), and Hong Kong (14.3%)
was reported, and the development of strains resistant to
levofloxacin in Qatar, Kuwait, Lebanon raised serious
concerns [12,13]. In addition, a research in southern
Nigeria confirmed that the level of resistance to first-
generation quinolones is relatively higher than that to
third-generation quinolones, i.e., the highest resistance is
to nalidixic acid and the least resistance is to levofloxacin
[14]. In this study, we investigated the prevalence of
mutations in the parE, parC, and gyrA genes and their
role in the development of quinolone resistance. Similar
to the findings of other investigations, our results showed
the highest prevalence of mutations regarded to the parC
gene with 75.56%. The prevalence of this gene was re-
ported to be 67.3% in 2001 in the United States [15], and
21.9% in 2005 [16] and 70% in 2009 in Italy [5]. We
studied both mutations and their effects on the rate of
quinolone resistance (Table 3). Similar to the findings of
Credito et al [17] and Jorgensen et al [18], our findings
imply that only mutations in the parC or gyrA gene were
resistant to ciprofloxacin, susceptible to ofloxacin, and
semisusceptible to levofloxacin. However, the isolates
that had simultaneous mutations in both genes were
completely resistant to ofloxacin and levofloxacin [9].
However, there are various opinions about the parE gene
and its role in the development of resistance to quino-
lones; according to research by Kawamura et al [19] in
Japan and Credito et al [17] in the United States, isolates
that had parE genemutations, alongwithmutations in the
parCor gyrAgene, had higher resistance to ciprofloxacin,
ofloxacin, norfloxacin, and lorfloxacin than mutants that
did not have mutations in the parE gene. Our finding is
contrary to the results of Ip et al [20], which showed that
the strains possess mutations in the parE gene are sus-
ceptible to quinolones and have no difference from the
wild strains. In contrast to Ip et al’s [20] results, for the
first time in Iran, we illustrated that there is a significant
250 M. Kargar, et alcorrelation between mutations in the parE gene and
resistance to norfloxacin, as strains that had mutations in
the parC or gyrA gene along with mutations in the parE
gene showed higher levels of resistance to this antibiotic.
In this study, in contrast to the previous thinking about
the role of mutation in the parE gene and resistance to
quinolones, the effect of mutations in the parE gene that
consequently cause low-level resistance to quinolones has
been determined. These results are arguable, and more
accurate studies investigating precise sequencing of a
gene are required. In addition, it is shown thatmutations in
the parC or gyrA gene play the most effective role in the
development of resistance to quinolones, as mutations in
either the parC or the gyrA gene alone can lead to low-
level quinolone resistance, while simultaneous muta-
tions in both parC and gyrA genes will bring about high-
level resistance. The prevalence of mutations in QRDRs
in S. pneumoniae strains and the subsequent development
of antibiotic resistance to different generations of quino-
lonesmay lead to the outbreak of antimicrobial resistance,
complicating the treatment of infections in the future.
Therefore, precautionary measures for the treatment and
control of resistancemust be adopted to prevent the spread
of resistant mutant strains.Conflicts of interest
All contributing authors declare no conflicts of
interest.
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